4.9 (575) In stock
Dana-Farber Cancer Institute researcher details promise, peril of CAR T-cell therapy, which enlists body’s immune system to fight disease.
FDA warns of rare secondary cancer risk with CAR-T therapies
Why There's a Severe Shortage of Cancer Drugs
FDA approves exagamglogene autotemcel to treat beta-thalassemia
Jason King posted on LinkedIn
Archives — Page 5 of 875 — Harvard Gazette
Carvykti CAR-T gets warning label - STAT
Regeneron hit with FDA rejection for blood cancer therapy - Clinical Trials Arena
As the War on Cancer Turns 50, Treatments Are Improving
Eric Smith (@ESmithMDPhD) / X
Susan B. Nichols on LinkedIn: Eyes On The Prize: The Latest Developments in Retinal Gene Therapies
